Under the background of the Internet plus era, Ddu is set up by a a talented team, consisting of experienced insiders and Internet elites. Ddu (Drugdu.com) is a global leading pharmaceuticals and medical devices B2B online platform. Different from comprehensive B2B platforms, Ddu is a vertical one focusing on the medical trade industry. It is a bold attempt for traditional industry to accelerate the transformation and upgrading.
INTERPHEX JAPAN will be held in Big Sight, Tokyo from June 28th - 30th. As the leading global pharmaceuticals and medical devices B2B online platform, Ddu will attend the fair with products from high priority members.
It is delighted that Chang'an Pharmaceutical became the 100th VIP member of Ddu. It is Ddu’s honor to invite Chang'an Pharmaceutical for the interview. Drugdu will continue to focus on the optimization of the online and offline services, committing to create more friendly, more humane medical trade ecosystem in the future.No matter it is the 1st member or the 1,000th one, Ddu will try the best. We are always with you.
The USFDA said that it has achieved a year early the target set for 2017, to take action on 90% of the applications pending prior to the start of the Generic Drug User Fee Amendment Act (GDUFA) of 2012.
Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that indicate the presence of cancer, enabling physicians to make quick, noninvasive diagnoses.
CPhI China 2017 will be held from 20th June to 22nd June 2017 at the Shanghai New International Expo Center (SNIEC) in Shanghai, China. Ddu, the leading global pharmaceuticals and medical devices B2B platform , will attend the exhibition with products from high-priority members and launch synchronization services of buy offers and agency service.
Merck has paused new enrolment in two studies assessing its immunotherapy Keytruda treatment in combination with other therapies in multiple myeloma to address safety concerns.
A new method for extracting prostate biopsies has been awarded a £789,000 Invention for Innovation (i4i) Product Development Award by the National Institute for Health Research (NIHR).
AbbVie’s upadacitinib has hit primary and secondary targets in the first late-stage trial of the drug involving patients with moderate-to-severe rheumatoid arthritis (RA).
Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.